Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cann Group ( (AU:CAN) ) has issued an announcement.
Cann Group Limited has announced changes in the director’s interest for Mr. Douglas Rathbone, Ms. Jennifer Pilcher, and Mr. Peter Kopanidis. These changes may affect the company’s governance and could have implications for its strategic direction, reflecting potential shifts in stakeholder interests and company operations.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited is a company focused on enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The company operates research facilities and corporate headquarters in Melbourne and has a large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group provides a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and globally. Additionally, the company owns Satipharm and its patent-protected capsule technology.
YTD Price Performance: -71.79%
Average Trading Volume: 4,227,982
Technical Sentiment Signal: Sell
Current Market Cap: A$13.9M
Learn more about CAN stock on TipRanks’ Stock Analysis page.